Biotechnology Data presented at the 27th European Academy of Dermatology and Venereology (EADV) in Paris, France, show that treatment with Kyntheum (brodalumab) for people with moderate to severe plaque psoriasis, was associated with a more rapid reduction in absolute Psoriasis Area Severity Index (PASI) scores and a greater probability of achieving complete skin clearance in all body regions compared with ustekinumab. 14 September 2018